Company Information
Bio-Gate AG
Neumeyerstrasse 28-34
90411 Nuernberg
Germany
Phone: +49 (0) 911 / 47 75 23 – 100
info@bio-gate.de
www.bio-gate.de
Press contact
Gerd Rückel
rikutis consulting
gr@rikutis.de
presse@bio-gate.de
Phone: +49 (0) 6172 807309
Mobile: +49 (0)152 34221966
Vector graphicCompany Information
Bio-Gate AG
Neumeyerstrasse 28-34
90411 Nuernberg
Germany
Phone: +49 (0) 911 / 47 75 23 – 100
info@bio-gate.de
www.bio-gate.de
Press contact
Gerd Rückel
rikutis consulting
gr@rikutis.de
presse@bio-gate.de
Phone: +49 (0) 6172 807309
Mobile: +49 (0)152 34221966
About Bio-Gate AG
Bio-Gate AG is technology health company and is one of the world's leading providers of innovative technologies and individual solutions for health and hygiene, which can make living together safer, more carefree and healthier and improve the well-being of every individual. Bio-Gate specializes in providing materials and surfaces with antiviral and antimicrobial properties. Bio-Gate AG refines materials and products, especially in the field of medical technology, such as the coating of implants or wound dressings. In addition, Bio-Gate technologies are used to uniquely enhance topical wound care products, skincare and cosmetics, consumer and industrial products such as paints and varnishes and antimicrobial plastics.
This publication constitutes neither an offer to sell nor an invitation to buy securities. The shares in Bio-Gate AG (the "Shares") may not be offered or sold in the United States or to or for the account or benefit of "U.S. persons" (as such term is defined in Regulation S under the U.S. Securities Act of 1933, as amended (the "Securities Act")). The securities have already been sold.
Publications
Bio-Gate offers effective infection prevention in human medicine with HyProtectTM technology
Published on
/INS . Project partner launches study for CE approval of implants coated with HyProtect TM Unique selling proposition due to extremely low infection rate Prevention of implant-associated infections HyProtect TM technology is able to solve prevalent and recurring problems in the field of infection prevention in human medicine
Bio-Gate AG signs LOI with North American medical device manufacturer for trauma implants
Published on
/INS. Nuremberg/Bremen, August 2, 2023 - Bio-Gate AG (ISIN DE000BGAG981), a leading provider of innovative technologies and individual solutions for health and hygiene, has concluded a preliminary agreement (LOI, Letter-of-Intent) with a North American medical device manufacturer focusing on the trauma sector. The medical device manufacturer intends to use Bio-Gate's "HyProtect TM " coating process for its own implants in human medicine following the FDA approval process.
Bio-Gate and OSSIS expand into additional international markets with HyProtect™ Coatings on Compassionate Care implants.
Published on
Stronger and expanded international market access of OSSIS after acquisition by Zimmer Biomet Increased awareness of HyProtect™ coatings Increased volume of HyProtect™ coated implants
Bio-Gate concludes another cooperation agreement with leading multinational implant manufacturer
Published on
Medical technology business further strengthened Coating of orthopaedic revision implants with HyProtect technology Focus on protection against infections with multi-resistant germs Nuremberg/Bremen, 5 July 2022 – Bio-Gate AG (ISIN DE000BGAG981), a leading provider in the field of innovative health technologies, has concluded a contract with a leading multinational medical device manufacturer for the coating of orthopaedic implants in human medicine. As part of the cooperation and the joint project management, Bio-Gate is responsible for the application engineering and the production of the HyProtect coating and also supports the regulatory approval of the implants.
Bio-Gate and Avicanna complete first phase of development on CBD and Micro Silver BG™ based skin care products for global commercialization
Published on
Entry into another growth market through cooperation with Avicanna Inc. (TSX: AVCN) Products with synergistic properties of MicroSilver BG and CBD (hemp derived) have been developed. Addressing dermatology and cosmetics markets with an initial focus on North America and Europe Nuremberg/Bremen, June 29 th 2021 – Bio-Gate AG (ISIN DE000BGAG981), a leading provider of innovative technologies and individual solutions for health and hygiene, has completed the initial development phase for prospective products through a licensing and development agreement with Avicanna Inc. (TSX: AVCN), a Canadian bio-pharmaceutical company, to enter the rapidly growing cannabidiol (CBD) market.